CN105769797B - A kind of kushenin osmotic pump controlled release tablet and preparation method thereof - Google Patents
A kind of kushenin osmotic pump controlled release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN105769797B CN105769797B CN201610141872.9A CN201610141872A CN105769797B CN 105769797 B CN105769797 B CN 105769797B CN 201610141872 A CN201610141872 A CN 201610141872A CN 105769797 B CN105769797 B CN 105769797B
- Authority
- CN
- China
- Prior art keywords
- kushenin
- semi
- label
- controlled release
- osmotic pump
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to pharmaceutical controlled release formulation technical fields, specifically disclose a kind of kushenin osmotic pump controlled release tablet, also disclose preparation method.Kushenin osmotic pump controlled release tablet is made of the moisture-proof protective film outside plain piece and plain piece, and plain piece is made of the semi-permeable membrane outside label and label, and there are one release holes for setting on semi-permeable membrane；Label is made of the raw material of following weight percent content：Kushenin 40.00%~60.00%, sodium chloride 15.00%~25.00%, lactose 20.00%~30.00%, hydroxypropyl methyl cellulose 2.00% 5.00%, polyvinylpyrrolidone 1.00%~3.50%, magnesium stearate 0.50%~2.00%.Kushenin osmotic pump controlled release tablet provided by the invention keeps good zero-order release in 20 hours, and for final Cumulative release amount more than 70%, the final Cumulative release amount in part is more than 80%, can be clinically used for the treatment of chronic viral hepatitis type B.
Description
Technical field
The present invention relates to pharmaceutical controlled release formulation technical field, more particularly to a kind of kushenin osmotic pump controlled release tablet, simultaneously also
It is related to preparation method.
Background technology
Kushenin, alias oxymatrine, Fick gunter derive from Sophora alopecuroide.Sophora alopecuroide is that one kind being grown in China west
The cassia leguminous plant in backlands area, according to《Sheng Nong's herbal classic》It carries, Sophora alopecuroide has the work(such as heat-clearing, dampness removing, wind-dispelling, desinsection, removing toxic substances
Effect.The effective ingredient of kushenin is oxymatrine and a small amount of N-Oxysophocarpine.In recent years to the pharmacology of kushenin and clinic
Research in find, with multiple pharmacological effects such as antiviral, decompression, anti-arrhythmia cordis, especially chronic hepatitis is controlled
Treatment has obtained good curative effect, and adverse reaction is less.
Treatment for chronic hepatitis, Western medicine mainly use interferon medicine medicine similar with nucleosides, the kushenin quilt of Chinese medicine
It is considered have good hepatitis virus resisting to act on and improve liver function effect, becomes clinically widely applied a kind of production at present
Product., with the patient of antiviral indication, hardship is used for not being resistant to or being unwilling receive interferon and ucleosides treatment
The plain combined immunization of ginseng adjusts drug tool and has a better effect.Research of the oxymatrine in terms for the treatment of virus hepatitis in recent years
It was found that oxymatrine has direct Anti-hepatitis B virus effects, collagen mobility and prevention liver fibrosis can be inhibited, can be hindered
Disconnected liver cell aberrant apoptosis, oxymatrine have protective effect to Experimental Mice hepatic failure.Oxymatrine in treating patients with chronic hepatitis
The clinical practice of hepatitis also obtains good efficacy, has the Chronic Hepatitis B that leucocyte and blood platelet reduce, by Oxymatrine
After alkali treatment, 1/3 patient's leucocyte and platelet recovery are normal, or have different degrees of raising, while finding that oxymatrine is controlled
Treatment group serum Collagen Type VI and hyaluronic acid level are decreased significantly before relatively treating, and show oxymatrine in treating patients with chronic hepatitis hepatitis
Have simultaneously and inhibits collagen mobility and fibrosis effect.On the whole, oxymatrine, which has, inhibits HCV proliferation, anti-liver fine
Dimensionization and the effect for adjusting host immune.
A kind of kushenin osmotic pump type controlled release preparation and its system are disclosed in the patent application of Publication No. CN 1480137A
Preparation Method, said preparation have 24 hours controlled-release functions, and controlled release tablet is by kushenin, diluent, penetration enhancer, lubricant, viscous
The compositions such as mixture, every piece weight of the kushenin controlled release tablet be 580mg, due to kushenin raw material be highly dissoluble, high osmosis at
Point, stabilizer is not added in side at which, is easy to that phenomenon of burst release occurs in vitro in dissolution test；Simultaneously on semi-permeable membrane
For mechanical punching, the aperture between piece differs greatly the hole knockout used, it is difficult to accomplish scale production.
The patent application of Publication No. CN 101584676A discloses a kind of Kurarinol slow-release piece and preparation method thereof, should
Sustained release tablets have 16 hours slow releasing functions, mainly by kushenin, lactose, microcrystalline cellulose, PVP K-30 ethanol solution, hydroxyl
Third methylcellulose, magnesium stearate, stomach dissolution type coating coating powder composition, the sustained release tablets discharged 30% or so at 0-2 hours, and 6 is small
When release 60% or so, release 80% or so in 12 hours, release 90% or so in 16 hours has certain slow release characteristic, but preceding
Phase release is very fast, fails the stabilization constant release for realizing drug, i.e. Zero order release feature, and patient still needs to take medicine 2 times for 1st.
For these reasons, it is necessary to a kind of kushenin controlled release preparation be provided, drug release is made to stablize, avoid the occurrence of burst release
Phenomenon, and can nearly constant speed release medicine, increase drug release controllability, make the availability higher of drug.
Invention content
The invention mainly solves the technical problem of providing a kind of kushenin osmotic pump controlled release tablets, are kept in 20 hours
Good zero-order release, for final Cumulative release amount more than 70%, the final Cumulative release amount in part is more than 80%, can be clinically used for
The treatment of chronic viral hepatitis type B.
A kind of preparation method of kushenin osmotic pump controlled release tablet is provided present invention solves the technical problem that also residing in.
In order to solve the above technical problems, the technical solution adopted by the present invention is：A kind of kushenin osmotic pump controlled release tablet, it is described
Kushenin osmotic pump controlled release tablet is made of plain piece and the moisture-proof protective film being wrapped in outside the plain piece, and the plain piece is by label and packet
The semi-permeable membrane being rolled in outside the label forms, and there are one release holes for setting on the semi-permeable membrane；
The label is made of the raw material of following weight percent content：
Kushenin 40.00%~60.00%,
Sodium chloride 15.00%~25.00%,
Lactose 20.00%~30.00%,
Hydroxypropyl methyl cellulose 2.00%-5.00%,
Polyvinylpyrrolidone 1.00%~3.50%,
Magnesium stearate 0.50%~2.00%；
The weight of the label is 350.00~450.00mg.
Optionally, the semi-permeable membrane coating solution for preparing the semi-permeable membrane is made of the raw material of following weight percent content：
Cellulose acetate 3.50%~3.80%, polyethylene glycol-4000 0.25%~0.27%, phthalic acid diethyl
Ester 0.35%~0.38%, water 2.18%~2.34%, acetone 93.37%~93.56%.
Optionally, the moistureproof coating liquid for preparing the moisture-proof protective film is made of the raw material of following weight percent content：
IV acrylic resins 7.0%~8.0%, talcum powder 1.3%~1.5%, magnesium stearate 1.3%~1.5%, nothing
Water-ethanol 89.0%~90.4%.
Preferably, the content of kushenin is 180~210mg in the kushenin osmotic pump controlled release tablet.
The release hole being arranged on the semi-permeable membrane is formed by laser boring, pore size 0.5mm.
Preferably, the label is made of the raw material of following weight percent content：
Kushenin 50.00%, sodium chloride 20.00%, lactose 24.00%, hydroxypropyl methyl cellulose 3.75%, polyethylene
Pyrrolidones 1.25%, magnesium stearate 1.00%.
It is further preferred that the weight of the label is 400.00mg.
A kind of preparation method of kushenin osmotic pump controlled release tablet, including step：
(1) label is prepared
Raw material is weighed by following weight percent content composition：
Kushenin 40.00%~60.00%,
Sodium chloride 15.00%~25.00%,
Lactose 20.00%~30.00%,
Hydroxypropyl methyl cellulose 2.00%-5.00%,
Polyvinylpyrrolidone 1.00%~3.50%,
Magnesium stearate 0.50%~2.00%；
Kushenin crosses 200 mesh sieve, sodium chloride, lactose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, magnesium stearate
It sieves with 100 mesh sieve respectively；Kushenin, sodium chloride, lactose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone mixing, cross 100 mesh
Sieve 2 times adds suitable anhydrous alcohol for medical use and makees wetting agent stirring and be made softwood after mixing, crosses the sieve granulation of 30 mesh, obtains
To wet granular, the wet granular places dry 5h in 40 DEG C of baking ovens and magnesium stearate lubricant is then added with 20 mesh sieves
It is uniformly mixed, obtains dry particl, with tabletting machine, tableting die is the punch die in the apertures diameter 10mm, weighs Core formulation amount
Dry particl, carry out sheeting operation, label be made, the weight of the label is 350.00~450.00mg；
(2) semi-transparent film coating
Prepare semi-permeable membrane coating solution：The semi-permeable membrane coating solution of semi-permeable membrane is prepared by the raw material group of following weight percent content
At：
Cellulose acetate 3.50%~3.80%, polyethylene glycol-4000 0.25%~0.27%, phthalic acid diethyl
Ester 0.35%~0.38%, water 2.18%~2.34%, acetone 93.37%~93.56%；
Semi-permeable membrane coating operations carry out in coating pan, and coating process parameters are：40~45 DEG C of inlet air temperature, engine speed
8~12r/min enters the wind rotating speed 1100r/min, air draft rotating speed 1800r/min, 8.0~11.0r/min of wriggling revolution speed, atomization
Pressure 0.1MPa, in placing 5h in 40 DEG C of baking ovens after the completion of coating operations；
(3) laser boring
Using laser-beam drilling machine, punching pore size is 0.5mm；
(4) moisture protection film coating
Prepare moistureproof coating liquid：The moistureproof coating liquid of moisture-proof protective film is prepared by the raw material group of following weight percent content
At：
IV acrylic resins 7.0%~8.0%, talcum powder 1.3%~1.5%, magnesium stearate 1.3%~1.5%, nothing
Water-ethanol 89.0%~90.4%；
Moistureproof coating operation carries out in coating pan, and coating process parameters are：47~53 DEG C of inlet air temperature, engine speed 8
~12r/min enters the wind rotating speed 1100r/min, air draft rotating speed 1800r/min, 2.0~3.0r/min of wriggling revolution speed, atomization pressure
Power 0.15MPa, coating operations are after the completion in placement 5h in 40 DEG C of baking ovens to get kushenin osmotic pump controlled release tablet.
Preferably, the label is made of the raw material of following weight percent content：
Kushenin 50.00%, sodium chloride 20.00%, lactose 24.00%, hydroxypropyl methyl cellulose 3.75%, polyethylene
Pyrrolidones 1.25%, magnesium stearate 1.00%.
It is further preferred that the weight of the label is 400.00mg.
In the course of the research, applicant has investigated auxiliary material in kushenin osmotic pump controlled-releasing tablet recipe by single factor experiment and has selected
It selects and its ratio, coating solution components select and its key factors such as proportioning, finally obtained the rational kushenin osmotic pumps of compounding
Controlled release tablet recipe can make drug in interior nearly constant release for 24 hours.The beneficial effects of the invention are as follows：Kushenin provided by the invention oozes
Saturating pump controlled-releasing tablet provides kushenin to human body, takes rear sustainable stable release 20 hours, burst size is about total content per hour
4.0%~5.0%, controllability is stronger, availability higher.In nearly constant release drug interior for 24 hours, released by the drug of nearly constant speed
Journey is let off, collagen mobility and prevention liver fibrosis is inhibited effectively to be kept away to play the role of anti-hepatitis B virus in vivo
The peak valley phenomenon for having exempted from drug blood concentration alleviates the toxicity of drug, reduces the medicining times of patient, and patient only needs
It is daily primary, it is easy to take medicine on time, substantially increases the compliance of patient, adapted to the needs of clinical development.
Kushenin osmotic pump controlled release tablet provided by the invention, after patient takes, the moisture-proof protective film of controlled release tablet outer layer exists
It is disintegrated rapidly in gastric juice, the hydrone in alimentary canal enters label through semi-permeable membrane, and label is made gradually to dissolve, and is oozed to produce
Lysate is released together with drug by release hole on semi-permeable membrane and enters gastrointestinal tract by saturating pressure difference, due to kushenin enteron aisle not
There was no significant difference for absorption in same position (duodenum, jejunum, ileum and colon), therefore different parts are close in vivo for drug
It can be efficiently absorbed after constant release.
Tests prove that kushenin osmotic pump controlled release tablet provided by the invention keeps good zero level to release in 20 hours
Medicine, for final Cumulative release amount more than 70%, the final Cumulative release amount in part is more than 80%, can be clinically used for chronic type b virus
The treatment of property hepatitis.
Description of the drawings
Fig. 1 is the structural schematic diagram for the kushenin osmotic pump controlled release tablet that 1-6 of the embodiment of the present invention is provided；
Fig. 2 is the drug release profiles comparison diagram for the kushenin osmotic pump controlled release tablet that 1-6 of the embodiment of the present invention is provided；
Fig. 3 is the releasing curve diagram of the kushenin osmotic pump controlled release tablet made from Core formulation 1- Core formulations 3 respectively；
Fig. 4 is the releasing curve diagram of the kushenin osmotic pump controlled release tablet made from Core formulation 4- Core formulations 6 respectively；
Fig. 5 is the releasing curve diagram of the kushenin osmotic pump controlled release tablet made from Core formulation 7, Core formulation 8 respectively；
Fig. 6 is the releasing curve diagram of the kushenin osmotic pump controlled release tablet made from Core formulation 9- Core formulations 11 respectively；
Fig. 7 is the releasing curve diagram of the kushenin osmotic pump controlled release tablet made from Core formulation 12- Core formulations 14 respectively；
Fig. 8 is the kushenin osmotic pump controlled-releasing made from semi-permeable membrane coating fluid prescription 1, semi-permeable membrane coating fluid prescription 2 respectively
The releasing curve diagram of piece；
Fig. 9 is the kushenin osmotic pump controlled-releasing made from semi-permeable membrane coating fluid prescription 3, semi-permeable membrane coating fluid prescription 4 respectively
The releasing curve diagram of piece；
Figure 10 is the kushenin osmotic pump controlled-releasing made from semi-permeable membrane coating fluid prescription 5- semi-permeable membranes coating fluid prescription 7 respectively
The releasing curve diagram of piece；
Figure 11 is that the kushenin osmotic pump controlled release tablet for not carrying out moistureproof coating and kushenin after moistureproof coating are osmotic pump controlled
Release piece vitro release comparison diagram.
Specific implementation mode
The technical scheme of the invention is described in detail through specific implementation examples.
Embodiment 1
As shown in Figure 1, a kind of kushenin osmotic pump controlled release tablet, by plain piece and 4 groups of moisture-proof protective film being wrapped in outside plain piece
At plain piece is made of label 2 and the semi-permeable membrane 3 being wrapped in outside label 2, and there are one release holes 1 for setting on semi-permeable membrane 3；Release hole 1
It is formed by laser boring, pore size 0.5mm.
Label 2 is made of the raw material of following weight percent content：
Kushenin 40.00%, sodium chloride 21.00%, lactose 30.00%, hydroxypropyl methyl cellulose 5.00%, polyethylene
Pyrrolidones 3.50%, magnesium stearate 0.50%；The weight of label is 450.00mg.
The semi-permeable membrane coating solution for preparing semi-permeable membrane 3 is made of the raw material of following weight percent content：
Cellulose acetate 3.50%, polyethylene glycol-4000 0.25%, diethyl phthalate 0.35%, water
2.34%, acetone 93.56%.
The moistureproof coating liquid for preparing moisture-proof protective film 4 is made of the raw material of following weight percent content：
IV acrylic resins 7.0%, talcum powder 1.3%, magnesium stearate 1.3%, absolute ethyl alcohol 90.4%.
The preparation method of the present embodiment kushenin osmotic pump controlled release tablet, including step：
(1) label is prepared
Each raw material is weighed by above weight percent content composition, kushenin crosses 200 mesh sieve, sodium chloride, lactose, hydroxypropyl
Methylcellulose, polyvinylpyrrolidone, magnesium stearate sieve with 100 mesh sieve respectively；Kushenin, sodium chloride, lactose, hydroxypropyl methyl
Cellulose, polyvinylpyrrolidone mixing sieve with 100 mesh sieve 2 times, after mixing, add suitable anhydrous alcohol for medical use and make
Softwood is made in wetting agent stirring, crosses the sieve granulation of 30 mesh, obtains wet granular, wet granular places dry 5h in 40 DEG C of baking ovens, with 20
Then mesh sieve is added magnesium stearate lubricant and is uniformly mixed, obtains dry particl, with tabletting machine, tableting die is straight
The punch die in the apertures diameter 10mm weighs the dry particl of Core formulation amount, carries out sheeting operation, and label is made, and the weight of label is
450.00mg；
(2) semi-transparent film coating
Semi-permeable membrane coating solution is prepared according to the composition of the present embodiment semi-permeable membrane coating solution, is then coated process, half
Permeable membrane coating operations carry out in coating pan, and coating process parameters are：45 DEG C, engine speed 12r/min of inlet air temperature, air inlet turn
Fast 1100r/min, air draft rotating speed 1800r/min, wriggling revolution speed 11.0r/min, atomizing pressure 0.1MPa, coating operations are completed
Afterwards in placing 5h in 40 DEG C of baking ovens；
(3) laser boring
Using laser-beam drilling machine, punching pore size is 0.5mm；
(4) moisture protection film coating
Moistureproof coating liquid is prepared according to the composition of the present embodiment moistureproof coating liquid, is then coated process, moisture-proof packet
Clothing operation carries out in coating pan, and coating process parameters are：47 DEG C, engine speed 8r/min of inlet air temperature enters the wind rotating speed
1100r/min, air draft rotating speed 1800r/min, wriggling revolution speed 2.0r/min, atomizing pressure 0.15MPa, after the completion of coating operations
In placement 5h in 40 DEG C of baking ovens to get kushenin osmotic pump controlled release tablet.
Embodiment 2
As shown in Figure 1, a kind of kushenin osmotic pump controlled release tablet, by plain piece and 4 groups of moisture-proof protective film being wrapped in outside plain piece
At plain piece is made of label 2 and the semi-permeable membrane 3 being wrapped in outside label 2, and there are one release holes 1 for setting on semi-permeable membrane 3；Release hole 1
It is formed by laser boring, pore size 0.5mm.
Label 2 is made of the raw material of following weight percent content：
Kushenin 40.00%, sodium chloride 25.00%, lactose 26.00%, hydroxypropyl methyl cellulose 4.75%, polyethylene
Pyrrolidones 2.75%, magnesium stearate 1.50%；The weight of label is 450.00mg.
The semi-permeable membrane coating solution for preparing semi-permeable membrane 3 is made of the raw material of following weight percent content：
Cellulose acetate 3.50%, polyethylene glycol-4000 0.25%, diethyl phthalate 0.35%, water
2.34%, acetone 93.56%.
The moistureproof coating liquid for preparing moisture-proof protective film 4 is made of the raw material of following weight percent content：
IV acrylic resins 7.0%, talcum powder 1.3%, magnesium stearate 1.3%, absolute ethyl alcohol 90.4%.
Embodiment 3
As shown in Figure 1, a kind of kushenin osmotic pump controlled release tablet, by plain piece and 4 groups of moisture-proof protective film being wrapped in outside plain piece
At plain piece is made of label 2 and the semi-permeable membrane 3 being wrapped in outside label 2, and there are one release holes 1 for setting on semi-permeable membrane 3；Release hole 1
It is formed by laser boring, pore size 0.5mm.
Label 2 is made of the raw material of following weight percent content：
Kushenin 60.00%, sodium chloride 15.00%, lactose 20.00%, hydroxypropyl methyl cellulose 2.75%, polyethylene
Pyrrolidones 1.25%, magnesium stearate 1.00%；The weight of label is 350.00mg.
The semi-permeable membrane coating solution for preparing semi-permeable membrane 3 is made of the raw material of following weight percent content：
Cellulose acetate 3.80%, polyethylene glycol-4000 0.27%, diethyl phthalate 0.38%, water
2.18%, acetone 93.37%.
The moistureproof coating liquid for preparing moisture-proof protective film 4 is made of the raw material of following weight percent content：
IV acrylic resins 8.0%, talcum powder 1.5%, magnesium stearate 1.5%, absolute ethyl alcohol 89.0%.
Embodiment 4
As shown in Figure 1, a kind of kushenin osmotic pump controlled release tablet, by plain piece and 4 groups of moisture-proof protective film being wrapped in outside plain piece
At plain piece is made of label 2 and the semi-permeable membrane 3 being wrapped in outside label 2, and there are one release holes 1 for setting on semi-permeable membrane 3；Release hole 1
It is formed by laser boring, pore size 0.5mm.
Label 2 is made of the raw material of following weight percent content：
Kushenin 60.00%, sodium chloride 15.00%, lactose 20.00%, hydroxypropyl methyl cellulose 2.00%, polyethylene
Pyrrolidones 1.00%, magnesium stearate 2.00%；The weight of label is 350.00mg.
The semi-permeable membrane coating solution for preparing semi-permeable membrane 3 is made of the raw material of following weight percent content：
Cellulose acetate 3.80%, polyethylene glycol-4000 0.27%, diethyl phthalate 0.38%, water
2.18%, acetone 93.37%.
The moistureproof coating liquid for preparing moisture-proof protective film 4 is made of the raw material of following weight percent content：
IV acrylic resins 8.0%, talcum powder 1.5%, magnesium stearate 1.5%, absolute ethyl alcohol 89.0%.
Embodiment 5
As shown in Figure 1, a kind of kushenin osmotic pump controlled release tablet, by plain piece and 4 groups of moisture-proof protective film being wrapped in outside plain piece
At plain piece is made of label 2 and the semi-permeable membrane 3 being wrapped in outside label 2, and there are one release holes 1 for setting on semi-permeable membrane 3；Release hole 1
It is formed by laser boring, pore size 0.5mm.
Label 2 is made of the raw material of following weight percent content：
Kushenin 50.00%, sodium chloride 20.00%, lactose 24.00%, hydroxypropyl methyl cellulose 3.75%, polyethylene
Pyrrolidones 1.25%, magnesium stearate 1.00%；The weight of label is 400.00mg.
The semi-permeable membrane coating solution for preparing semi-permeable membrane 3 is made of the raw material of following weight percent content：
Cellulose acetate 3.60%, polyethylene glycol-4000 0.26%, diethyl phthalate 0.36%, water
2.23%, acetone 93.55%.
The moistureproof coating liquid for preparing moisture-proof protective film 4 is made of the raw material of following weight percent content：
IV acrylic resins 7.5%, talcum powder 1.4%, magnesium stearate 1.4%, absolute ethyl alcohol 89.7%.
Embodiment 6
As shown in Figure 1, a kind of kushenin osmotic pump controlled release tablet, by plain piece and 4 groups of moisture-proof protective film being wrapped in outside plain piece
At plain piece is made of label 2 and the semi-permeable membrane 3 being wrapped in outside label 2, and there are one release holes 1 for setting on semi-permeable membrane 3；Release hole 1
It is formed by laser boring, pore size 0.5mm.
Label 2 is made of the raw material of following weight percent content：
Kushenin 50.00%, sodium chloride 18.00%, lactose 27.00%, hydroxypropyl methyl cellulose 2.50%, polyethylene
Pyrrolidones 1.50%, magnesium stearate 1.00%；The weight of label is 400.00mg.
The semi-permeable membrane coating solution for preparing semi-permeable membrane 3 is made of the raw material of following weight percent content：
Cellulose acetate 3.60%, polyethylene glycol-4000 0.26%, diethyl phthalate 0.36%, water
2.23%, acetone 93.55%.
The moistureproof coating liquid for preparing moisture-proof protective film 4 is made of the raw material of following weight percent content：
IV acrylic resins 7.5%, talcum powder 1.4%, magnesium stearate 1.4%, absolute ethyl alcohol 89.7%.
The preparation method for the kushenin osmotic pump controlled release tablet that embodiment 2- embodiments 6 provide can refer to the progress of embodiment 1,
Middle parameter inlet air temperature, engine speed, wriggling revolution speed can be adjusted selection in the range of requiring, and can implement.
Test example
1, the kushenin osmotic pump controlled release tablet effect test that embodiment 1-6 is provided
Drug release test is carried out to 1-6 of the embodiment of the present invention kushenin osmotic pump controlled release tablets provided, obtained song
Line comparison diagram is as shown in Figure 2.As seen from Figure 2, each embodiment kushenin osmotic pump controlled release tablet is kept good in 20 hours
Good zero-order release, final Cumulative release amount more than 70%, embodiment 5, embodiment 6 final Cumulative release amount be more than
80%.Rear sustainable stable release 20 hours is taken, burst size is about the 4.0%~5.0% of total content per hour, and controllability is more
By force, availability higher.
The kushenin osmotic pump controlled release tablet that 1-6 of the embodiment of the present invention is provided complies fully with quality control requirement, releases in vitro
Degree of putting is measured with reference to drug release determination method (two the first methods of annex XD of Chinese Pharmacopoeia version in 2010) and dissolution method (China
Two the first methods of annex XC of pharmacopeia version in 2010) it is measured, it is desirable that 2 hours releases are 5%~15%, 6 hours releases
It is 20%~30%, 12 hours releases are 45%~65%, and release is 70%~85% within 20 hours, and 24 hours releases are not
It obtains and is less than 80%.
By the drug release process of nearly constant speed, inhibit collagen mobility and prevention liver fibrosis in vivo, to play
The effect of anti-hepatitis B virus effectively prevents the peak valley phenomenon of drug blood concentration, alleviates the toxicity of drug, subtracts
Lacking the medicining times of patient, patient only needs daily once, is easy to take medicine on time, substantially increases the compliance of patient,
The needs of clinical development are adapted to.
2, Core formulation, semi-permeable membrane coating fluid prescription and the experiment of moistureproof coating liquid prescription screening
2.1 Core formulations screen
Firstly the need of explanation, in Core formulation screening process, semi-permeable membrane coating fluid prescription is：Cellulose acetate
3.50%, polyethylene glycol-4000 0.25%, diethyl phthalate 0.35%, water 2.34%, acetone 93.56%；It is moisture-proof
Coating fluid prescription is：IV acrylic resins 7.5%, talcum powder 1.4%, magnesium stearate 1.4%, absolute ethyl alcohol 89.7%；
It is weight percent content above.
With the final accumulative releasing degree of In-vitro release curves and linear analogue coefficients R2To investigate target.
2.1.1 in label osmotically active ingredient screening
Lactose, mannitol, sodium chloride are individually selected in Core formulation, select hydroxypropyl methyl cellulose (HPMC-
K4M it) is used as retarding agent, magnesium stearate is selected to carry out pelletizing press sheet as lubricant, specific prescription is shown in Table 1.Respectively by label
The release profiles of kushenin osmotic pump controlled release tablet made from square 1- Core formulations 3 are as shown in Figure 3.
1 Core formulation 1-3 of table
| Supplementary material title | Prescription 1/mg | Prescription 2/mg | Prescription 3/mg |
| Kushenin | 200 | 200 | 200 |
| Sodium chloride | 180 | - | - |
| Lactose | - | 180 | - |
| Mannitol | - | - | 180 |
| HPMC-K4M | 16 | 16 | 16 |
| Magnesium stearate | 4 | 4 | 4 |
| It is total | 400 | 400 | 400 |
Releasing result according to fig. 3 is it is found that select sodium chloride, lactose osmotic pump controlled for the kushenin of osmotic pumps active constituent
Release that piece release profiles are almost the same, and select kushenin osmotic pump controlled release tablet release that mannitol is osmotic pumps active constituent compared with
Soon, 12h has discharged completely, and in order to adjust tabletting loading and hardness level, sodium chloride may be selected with lactose with the use of progress
Debugging.
2.1.2 in label osmotically active ingredient sodium chloride and galactose ratio screening
By consulting data of literatures, the osmotically active component content of osmotic pump controlled release tablet is prepared into ease of solubility ingredient
It should be the 35%~55% of label gross weight, the osmotically active ingredient total amount of this Formulation is subject to 45% (180mg), carries out
The investigation of sodium chloride and lactose different proportion, specific prescription are shown in Table 2.The kuh-seng made from Core formulation 4- Core formulations 6 respectively
The release profiles of plain osmotic pump controlled release tablet are as shown in Figure 4.
2 Core formulation 4-6 of table
| Supplementary material title | Prescription 4/mg | Prescription 5/mg | Prescription 6/mg |
| Kushenin | 200 | 200 | 200 |
| Sodium chloride | 60 | 90 | 120 |
| Lactose | 120 | 90 | 60 |
| HPMC-K4M | 16 | 16 | 16 |
| Magnesium stearate | 4 | 4 | 4 |
| It is total | 400 | 400 | 400 |
According to the releasing result of Fig. 4 it is found that when lactose and sodium chloride ratio are 2: 1 in prescription 4, release is linear preferable, but
Release is slightly relatively low compared with latter two prescription, but still (is more than 80%) in tolerance interval；And lactose and sodium chloride in prescription 6
Ratio be 1: 2 when, release is preferable, but for 24 hours in linearly dependent coefficient R2It is then not satisfactory；In comparison, work as lactose
When with sodium chloride ratio being 1: 1, release and linearly meet expection.Therefore, the proportional region of sodium chloride and lactose should select
It is selected as between 1: 1~1: 2.
2.1.3 in label retarding agent ingredient screening
Hydroxypropyl methyl cellulose (HPMC-K4M) and polyvinylpyrrolidone (PVP-K30) are selected respectively, select chlorination
Sodium (18.0%), lactose (27.0%) are osmotically active ingredient, select magnesium stearate to carry out pelletizing press sheet as lubricant, specifically
Prescription is shown in Table 3.Release profiles such as Fig. 5 institutes of the kushenin osmotic pump controlled release tablet made from Core formulation 7, Core formulation 8 respectively
Show.
3 Core formulation 7-8 of table
According to the releasing result of Fig. 5 it is found that HPMC-K4M is selected to be less than the latter as the prescription totality release of retarding agent,
Hardness in tabletting is less than normal, is easy to happen capping phenomenon, but its linearly dependent coefficient R2It is 0.9867, it is linear preferable；And it selects
Use PVP-K30 as retarding agent prescription totality release be higher than the former, but in vitro dissolution test when find have at part
Square piece is released in 6h, to improve overall accumulative releasing degree；Through consulting pertinent literature, slow control is made in ease of solubility main ingredient
It is easier to that phenomenon of burst release occurs when release formulation.It is found by our experimental study, suitable HPMC-K4M is added as retarding agent
Prescription can be effectively prevent to be released, although and PVP-K30 retardations are weak compared with HPMC-K4M, effectively acted as in pelletization
The effect of adhesive, therefore the two is indispensable.Further, the two ratio can be also suitably debugged to be investigated.
2.1.4 in label retarding agent ingredient HPMC-K4M and PVP-K30 ratios screening
By consulting data of literatures, the retardance stabiliser content that osmotic pump controlled release tablet is prepared into ease of solubility ingredient is answered
No more than the 10% of label gross weight, the retarding agent total amount of this Formulation is subject to 4% (16mg), carry out HPMC-K4M with
The investigation of PVP-K30 different proportions, specific prescription are shown in Table 4.The kushenin made from Core formulation 9- Core formulations 11 oozes respectively
The release profiles of saturating pump controlled-releasing tablet are as shown in Figure 6.
4 Core formulation 9-11 of table
According to the releasing result of Fig. 6 it is found that prescription 9 and the release profiles of prescription 10 are almost the same, release with it is linear
Coefficient R2Also in desired extent, but then there is phenomenon of burst release in prescription 11, therefore its release profiles shows part and releases
It puts and spends height and discharged complete phenomenon in 20h.It follows that the ratio of HPMC-K4M and PVP-K30 is answered in Core formulation
The control is in 5: 3~3: 1 range.
2.1.5 in label lubricant screening
It selects magnesium stearate, silica, talcum powder as lubricant in Core formulation respectively, selects sodium chloride
(18.0%), lactose (27.0%) is osmotically active ingredient, selects HPMC-K4M (3.75%), polyvinylpyrrolidone PVP-
K30 (1.25%) is adhesive, and specific prescription is shown in Table 5.The kushenin made from Core formulation 12- Core formulations 14 permeates respectively
The release profiles of pump controlled-releasing tablet are as shown in Figure 7.
5 Core formulation 12-14 of table
According to the releasing result of Fig. 7 it is found that selecting the release of the kushenin osmotic pump controlled release tablet of three kinds of lubricants bent respectively
Line is essentially identical, its angle of repose is measured after total mix and also selects magnesium stearate conduct without significant difference in order to save production cost
Lubricant.
2.2 semi-permeable membrane coating fluid prescriptions are screened
Firstly the need of explanation, in semi-permeable membrane coating fluid prescription screening process, Core formulation is：Kushenin 49.00%, chlorine
Change sodium 18.00%, lactose 27.00%, hydroxypropyl methyl cellulose 3.75%, polyvinylpyrrolidone 1.25%, magnesium stearate
1.00%, it is weight percent content above；The weight of label is 400.00mg.Moistureproof coating liquid prescription is：No. IV third
Olefin(e) acid resin 7.5%, talcum powder 1.4%, magnesium stearate 1.4%, absolute ethyl alcohol 89.7%.
With the final accumulative releasing degree of In-vitro release curves and linear analogue coefficients R2To investigate target.
2.2.1 in semi-permeable membrane coating solution pore-foaming agent screening
Pore-foaming agent selects polyethylene glycol-1500 (PEG 1500), polyethylene glycol-4000 (PEG respectively in semi-permeable membrane coating solution
4000) it is, filmogen with cellulose acetate (CA), and plasticizer phthalic acid diethylester (DEP) is added, specific prescription is shown in
Table 6.The release of the kushenin osmotic pump controlled release tablet made from semi-permeable membrane coating fluid prescription 1, semi-permeable membrane coating fluid prescription 2 is bent respectively
Line is as shown in Figure 8.
6 semi-permeable membrane coating fluid prescription 1-2 of table
| Supplementary material title | Prescription 1 | Prescription 2 |
| CA | 22.9g | 22.9g |
| PEG 4000 | 2.80g | - |
| PEG 1500 | - | 2.80g |
| DEP | 2.29g | 2.29g |
| Acetone | 750mL | 750mL |
| Water | 10mL | 10mL |
According to the releasing result of Fig. 8 it is found that it is the prescription totally release that pore-foaming agent carries out film coating to select PEG 4000
Degree is higher than the latter, it may be possible to which it is with better hydrophilic interaction, and pore effect is more preferable, and PEG 1500 is in use
It was found that it is easy softening, it is inconvenient when weighing, thus PEG 4000 is selected to be used as pore-foaming agent.
2.2.2 in semi-permeable membrane coating solution plasticizer screening
An addition diethyl phthalate (DEP) in this screening semi-permeable membrane coating fluid prescription, another does not add then
Add DEP, it is filmogen both to use cellulose acetate (CA), pore-foaming agent PEG 4000 is added, specific prescription is shown in Table 7.Respectively
Release profiles such as Fig. 9 of the kushenin osmotic pump controlled release tablet made from semi-permeable membrane coating fluid prescription 3, semi-permeable membrane coating fluid prescription 4
It is shown.
7 semi-permeable membrane coating fluid prescription 3-4 of table
| Supplementary material title | Prescription 3 | Prescription 4 |
| CA | 22.9g | 22.9g |
| PEG 4000 | 2.80g | 2.80g |
| DEP | 2.29g | - |
| Acetone | 750mL | 750mL |
| Water | 10mL | 10mL |
According to the releasing result of Fig. 9 it is found that the prescription for adding plasticizer DEP in semi-permeable membrane coating solution discharges linear R2For
0.9784, and the prescription for being not added with plasticizer DEP discharges linear R2It is 0.9217, therefore can effectively improve and release after addition plasticizer
Unwrapping wire makes its release closer to Zero order release, therefore selects a small amount of DEP of addition as plasticising in semi-permeable membrane coating fluid prescription
Agent.
2.2.3 in semi-permeable membrane coating solution pore-foaming agent dosage screening
By inquiring pertinent literature, the pore-foaming agent common dose solid content percentage in film coating is 6.0%~
20.0% (being converted into total content percentage about 0.20%~0.60%).This screening selection solid content percentage 6.0%,
10.0% and 15.0% carries out film coating respectively, and (it is respectively 0.20%, 0.25% and to be converted into total content percentage
0.30%) it is, filmogen with cellulose acetate (CA), and plasticizer phthalic acid diethylester (DEP), specific prescription is added
It is shown in Table 8.The release of the kushenin osmotic pump controlled release tablet made from semi-permeable membrane coating fluid prescription 5- semi-permeable membranes coating fluid prescription 7 respectively
Curve is as shown in Figure 10.
8 semi-permeable membrane coating fluid prescription 5-7 of table
| Supplementary material title | Prescription 5 | Prescription 6 | Prescription 7 |
| CA | 24.02g | 22.91g | 22.51g |
| PEG 4000 | 1.68g | 2.80g | 4.20g |
| DEP | 2.29g | 2.29g | 2.29g |
| Acetone | 750mL | 750mL | 750mL |
| Water | 10mL | 10mL | 10mL |
According to the releasing result of Figure 10 it is found that in semi-permeable membrane coating solution pore-foaming agent PEG 4000 solid content percentage pair
Vitro release has large effect, and when the solid content percentage of PEG 4000 is 6%, overall release is significantly lower than
The former, mainly since its content is relatively low, pore effect is on the weak side；And when the solid content percentage of PEG 4000 is 15%,
Overall release is fast, and release is complete substantially by 12~16h, is unable to reach the effect of Zero order release for 24 hours；In comparison, work as PEG
When 4000 solid content percentage is 10%, overall release is linear preferably with release.Therefore by comparing, EG is selected
4000 solid content percentage is that 10% (it is about 0.25% to be converted into total content percentage) is preferable.
2.3 moistureproof coating liquid prescription screenings
Moistureproof coating liquid prescription is selected：IV acrylic resins 7.0%~8.0%, talcum powder 1.3%~1.5%, tristearin
Sour magnesium 1.3%~1.5%, absolute ethyl alcohol 89.0%~90.4%；Coating parameter is：47~53 DEG C of inlet air temperature, engine speed 8
~12r/min enters the wind rotating speed 1100r/min, air draft rotating speed 1800r/min, 2.0~3.0r/min of wriggling revolution speed, atomization pressure
Power 0.15MPa observes finished product sheet by practical coating operations, and surface color is uniform, has preferable moisture-proof moist
Can, vitro release comparison is carried out with the prescription for not carrying out moistureproof coating, release profiles comparison diagram is as shown in Figure 11.
According to the releasing result of Figure 11 it is found that the In-vitro release curves of kushenin controlled release tablet and being not affected by shadow after moistureproof coating
It rings, two release profiles are consistent substantially, are illustrated that the moistureproof coating prescription can make tablet appearance keep beautiful, are had both moisture resistance
It can be without influencing its release.
The kushenin osmotic pump controlled release tablet by wrapping up one layer of semi-permeable membrane coatings in advance outside drug core, and semi-transparent
Laser boring is carried out on film coating layer, one layer of moistureproof coating layer is finally wrapped up on film-coating, to prevent label moisture absorption from failing.
After the controlled release tablet enters in vivo, moistureproof coating layer is directly dissolved and digests first, and body fluid passes through semi-permeable membrane film coating
Aperture and semi-permeable membrane enter label, and the sodium chloride in label and lactose water solubility are fabulous, to keep the osmotic pressure in piece apparent
Outside higher than piece, motive force caused by this permeable pressure head allows medicament to sustainedly and stably release from aperture, passes through
The key factors such as the proportioning of auxiliary material proportion, coating solution in single factor exploration prescription can finally be such that drug is released in nearly constant speed interior for 24 hours
It puts.
The above-mentioned description to embodiment is for the ease of those skilled in the art it will be appreciated that and using this
Case technology, those skilled in the art obviously can make various modifications to these embodiments easily, and described herein general
Principle is applied in other embodiments without having to go through creative labor.Therefore, this case is not limited to above example, this field
Technical staff according to the announcement of this case, the improvement made for this case and modification all should be in the protection domains of this case.
Claims (7)
1. a kind of kushenin osmotic pump controlled release tablet, which is characterized in that the kushenin osmotic pump controlled release tablet is by plain piece and is wrapped in
Moisture-proof protective film composition outside the plain piece, the plain piece is made of label and the semi-permeable membrane being wrapped in outside the label, described
There are one release holes for setting on semi-permeable membrane；
The label is made of the raw material of following weight percent content：
Kushenin 40.00%~60.00%,
Sodium chloride 15.00%~25.00%,
Lactose 20.00%~30.00%,
Hydroxypropyl methyl cellulose 2.00%-5.00%,
Polyvinylpyrrolidone 1.00%~3.50%,
Magnesium stearate 0.50%~2.00%；
The weight of the label is 350.00~450.00mg；
The semi-permeable membrane coating solution for preparing the semi-permeable membrane is made of the raw material of following weight percent content：Cellulose acetate
3.50%~3.80%, polyethylene glycol-4000 0.25%~0.27%, diethyl phthalate 0.35%~0.38%, water
2.18%~2.34%, acetone 93.37%~93.56%；
The moistureproof coating liquid for preparing the moisture-proof protective film is made of the raw material of following weight percent content：IV acrylic acid trees
Fat 7.0%~8.0%, talcum powder 1.3%~1.5%, magnesium stearate 1.3%~1.5%, absolute ethyl alcohol 89.0%~
90.4%；
The release hole being arranged on the semi-permeable membrane is formed by laser boring, pore size 0.5mm.
2. kushenin osmotic pump controlled release tablet according to claim 1, which is characterized in that the kushenin osmotic pump controlled release tablet
The content of middle kushenin is 180~210mg.
3. kushenin osmotic pump controlled release tablet according to claim 1, which is characterized in that the label is by following weight percent
Raw material than content forms：
Kushenin 50.00%, sodium chloride 20.00%, lactose 24.00%, hydroxypropyl methyl cellulose 3.75%, polyvinyl pyrrole
Alkanone 1.25%, magnesium stearate 1.00%.
4. kushenin osmotic pump controlled release tablet according to claim 3, which is characterized in that the weight of the label is
400.00mg。
5. a kind of preparation method of kushenin osmotic pump controlled release tablet, which is characterized in that including step：
(1) label is prepared
Raw material is weighed by following weight percent content composition：
Kushenin 40.00%~60.00%,
Sodium chloride 15.00%~25.00%,
Lactose 20.00%~30.00%,
Hydroxypropyl methyl cellulose 2.00%-5.00%,
Polyvinylpyrrolidone 1.00%~3.50%,
Magnesium stearate 0.50%~2.00%；
Kushenin crosses 200 mesh sieve, sodium chloride, lactose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, magnesium stearate difference
It sieves with 100 mesh sieve；Kushenin, sodium chloride, lactose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone mixing, sieve with 100 mesh sieve 2
It is secondary, it after mixing, adds anhydrous alcohol for medical use and makees wetting agent stirring and be made softwood, cross the sieve granulation of 30 mesh, obtain wet granular,
The wet granular places dry 5h in 40 DEG C of baking ovens, with 20 mesh sieves, magnesium stearate lubricant is then added and is uniformly mixed,
It is the punch die in the apertures diameter 10mm that tabletting machine, tableting die are used after mixing, label is made, the weight of the label is
350.00~450.00mg；
(2) semi-transparent film coating
Prepare semi-permeable membrane coating solution：The semi-permeable membrane coating solution for preparing semi-permeable membrane is made of the raw material of following weight percent content：
Cellulose acetate 3.50%~3.80%, polyethylene glycol-4000 0.25%~0.27%, diethyl phthalate
0.35%~0.38%, water 2.18%~2.34%, acetone 93.37%~93.56%；
Semi-permeable membrane coating operations carry out in coating pan, and coating process parameters are：40~45 DEG C of inlet air temperature, engine speed 8~
12r/min enters the wind rotating speed 1100r/min, air draft rotating speed 1800r/min, 8.0~11.0r/min of wriggling revolution speed, atomizing pressure
0.1MPa, in placing 5h in 40 DEG C of baking ovens after the completion of coating operations；
(3) laser boring
Using laser-beam drilling machine, punching pore size is 0.5mm；
(4) moisture protection film coating
Prepare moistureproof coating liquid：The moistureproof coating liquid for preparing moisture-proof protective film is made of the raw material of following weight percent content：
IV acrylic resins 7.0%~8.0%, talcum powder 1.3%~1.5%, magnesium stearate 1.3%~1.5%, anhydrous second
Alcohol 89.0%~90.4%；
Moistureproof coating operation carries out in coating pan, and coating process parameters are：47~53 DEG C of inlet air temperature, engine speed 8~
12r/min enters the wind rotating speed 1100r/min, air draft rotating speed 1800r/min, 2.0~3.0r/min of wriggling revolution speed, atomizing pressure
0.15MPa, coating operations are after the completion in placement 5h in 40 DEG C of baking ovens to get kushenin osmotic pump controlled release tablet.
6. the preparation method of kushenin osmotic pump controlled release tablet according to claim 5, which is characterized in that the label by with
The raw material of lower weight percent content forms：
Kushenin 50.00%, sodium chloride 20.00%, lactose 24.00%, hydroxypropyl methyl cellulose 3.75%, polyvinyl pyrrole
Alkanone 1.25%, magnesium stearate 1.00%.
7. the preparation method of kushenin osmotic pump controlled release tablet according to claim 6, which is characterized in that the weight of the label
Amount is 400.00mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610141872.9A CN105769797B (en) | 2016-03-11 | 2016-03-11 | A kind of kushenin osmotic pump controlled release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610141872.9A CN105769797B (en) | 2016-03-11 | 2016-03-11 | A kind of kushenin osmotic pump controlled release tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105769797A CN105769797A (en) | 2016-07-20 |
| CN105769797B true CN105769797B (en) | 2018-10-02 |
Family
ID=56393492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610141872.9A Active CN105769797B (en) | 2016-03-11 | 2016-03-11 | A kind of kushenin osmotic pump controlled release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105769797B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1480137A (en) * | 2003-07-04 | 2004-03-10 | 沈阳药科大学 | Osmotic pump type controlled release preparation of kurarinone and its preparing method |
-
2016
- 2016-03-11 CN CN201610141872.9A patent/CN105769797B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1480137A (en) * | 2003-07-04 | 2004-03-10 | 沈阳药科大学 | Osmotic pump type controlled release preparation of kurarinone and its preparing method |
Non-Patent Citations (2)
| Title |
|---|
| 苦参素微孔渗透泵片的研制;吴晓丽等;《中国药科大学学报》;20101231;第41卷(第1期);第45-49页 * |
| 苦参素渗透泵控释片的制备及释药影响因素考察;庞大海等;《中国药剂学杂志》;20050731;第3卷(第4期);第242-248页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105769797A (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11413295B2 (en) | Oral preparation of obeticholic acid | |
| CN106924208A (en) | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof | |
| WO2001034147A1 (en) | Oral solid preparation | |
| CN107595795A (en) | A kind of Metoprolol succinate sustained-release tablets and preparation method thereof | |
| CN104688700B (en) | A kind of tenofovir disoproxil fumarate piece and preparation method thereof for being easy to dissolve out | |
| CN102137663B (en) | The stable pharmaceutical preparation of suppression variable color | |
| CN103006612B (en) | Lisinopril controlled-release tablet and preparation method thereof | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN104814923B (en) | A kind of tamsulosin hydrochloride sustained release preparation and preparation method thereof and its application | |
| CN106176771A (en) | A kind of lamivudine tenofovir Compound Tablet and preparation method thereof | |
| CN103610658B (en) | Immunomodulator slow-release preparation and preparation method thereof | |
| CN106667936A (en) | Sofosbuvir tablet and preparation method thereof | |
| CN107334772A (en) | A kind of antiretroviral drugs composition | |
| CN105147628A (en) | TDF (tenofovir disoproxil fumarate) pellets and preparation method thereof | |
| CN105769797B (en) | A kind of kushenin osmotic pump controlled release tablet and preparation method thereof | |
| CN107982240B (en) | Potassium sodium dehydroandroan drographolide succinate enteric coated granules capable of being accurately dissolved out and preparation method thereof | |
| CN105616376B (en) | Composition and preparation method containing magnesium isoglycyrrhetate medicine | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN108853044B (en) | Nifedipine sustained release tablet and preparation method thereof | |
| CN110251476B (en) | Emtricitabine tenofovir pharmaceutical composition | |
| CN105748422B (en) | Pharmaceutical composition comprising enalapril and felodipine | |
| CN105168165B (en) | A kind of Lercanidipine hydrochloride piece and preparation method thereof | |
| CN103301074A (en) | Diammonium glycyrrhizinate enteric-coated pellet as well as preparation method and preparation thereof | |
| CN103622930B (en) | Metformin hydrochloride slow release preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |